Pharmaceutical Experience Matters in Defending Pharmaceutical Securities Cases
January 30, 2020
By: Matthew Becker
Axinn Update
It is no secret that the number of securities class actions filed against pharmaceutical companies has soared in recent years. From a historical average of 12 per year from 1997-2016, the number of securities cases against pharmaceutical companies rose to 30 in 2017 and 24 in 2018.1 In recent years, the pharmaceutical industry has been the single largest recipient of securities suits across all listed companies.
What is the best response to this tsunami of securities filings? A firm grasp of securities law fundamentals is obviously critical. But does expertise and experience in the pharmaceutical industry matter as well?
Recent case law shows that pharmaceutical industry knowledge can lead to better results in securities suits in the pharmaceutical industry. Stand-out early resolutions of securities claims against pharmaceutical companies reflect the defendant’s ability to talk knowledgeably about such industry-specific issues as:
- Clinical studies and special protocol reviews
- Interaction of patent applications with clinical studies
- Comparisons of a drug candidate with other drugs
- Significance of statements at various stages of clinical trials
- Pronouncements by the FDA and independent committees
These “technical” points go to the central securities-law elements of whether a misrepresentation was made, its materiality, the defendant’s scienter, and damages. In many industries, securities defense amounts to a formulaic consideration of these elements, with little regard to the industry at issue. As the cases discussed below attest, in the pharmaceutical world, industry experience can be crucial in constructing a winning securities defense.
The balance of this memorandum summarizes recent securities decisions illustrating the relevance of pharmaceutical industry knowledge and experience to the successful defense of securities claims against a pharmaceutical defendant.
Click here to access the entire memorandum.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
ACI 12th Annual Summit for Women Leaders in Life Sciences Law
Speaking Engagement
Intellectual Property
National LGBTQ+ Bar Association Lavender Law Conference and Career Fair 2025
Sponsorship
National Bar Association 100th Annual Convention and Exhibits
Sponsorship
Antitrust
Keeping Pace: Updates in Cartel Enforcement
Webinar
Antitrust
Informa Antitrust Midwest
Speaking Engagement
GCR Live: Law Leaders Europe 2025
Speaking Engagement
Antitrust
Axinn Counsel Rebecca Clegg Named 2025 MCCA Rising Star
Awards & Recognitions
Intellectual Property
Chambers Merger Control 2025 Guide
Byline Articles
Antitrust
Navigating the Hart-Scott-Rodino Act in 2025
Webinar
Antitrust
French Competition Enforcement in the New EU Paradigm
Axinn Viewpoints
Antitrust